Plain-English translation of NCT06414148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication given after CAR T-cell therapy, to see if it can help people with aggressive lymphoma stay in remission longer. Some patients will receive alone, while others will receive it combined with two additional drugs (lenalidomide and rituximab). The goal is to see which approach works best for people whose cancer shows signs of lingering disease even after CAR T-cell treatment.
Even after successful CAR T-cell therapy, some patients still have tiny amounts of cancer cells remaining that are not visible on standard scans. This trial is designed to test whether giving additional medication can eliminate these remaining cells and prevent the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You will receive 6 cycles of the assigned medication over several months, with check-ins after every 2 cycles. You'll have blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and check for side effects. After treatment ends, you'll continue with follow-up visits at months 12, 15, 18, and 24 to track your long-term response, and researchers will monitor your health for 2 years total from when the last participant enrolled.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Australia